Resonant buys Creapharm Bioservices

Resonant Clinical Solutions has bought Creapharm Bioservices, a France-based specialist in biobanking and cryogenic storage, in a deal announced on September 3. The seller was Myonex, a clinical trial supply and packaging company with operations in the United States, France and Germany. Resonant said the acquisition expands its European biorepository footprint and adds infrastructure for increasingly complex clinical programs, including cell and gene therapy trials. (prnewswire.com) The transaction is less about headline drug development than about the physical systems needed to run modern trials. (persportaal.anp.nl) Resonant describes itself as a clinical solutions partner serving life sciences organizations across the clinical supply chain and sample lifecycle, with services spanning sourcing, supply chain and storage. Creapharm adds specialized handling for sensitive biologic materials that cannot be managed like standard trial supplies. (prnewswire.com) ### What exactly did Resonant buy? Creapharm Bioservices is based in Bailly-Romainvilliers, France, and provides specialized biobanking and cryogenic storage for biotherapeutics, Advanced Therapy Medicinal Products and biological samples. Its capabilities include vapor-phase nitrogen storage down to minus 196 degrees Celsius, mechanical freezer and cold storage, GMP sample storage and GDP quality-control sample custody. (prnewswire.com) The September 3 announcement said Creapharm is now part of Resonant’s Biorepository business. Resonant said the addition broadens its global footprint and brings in expertise for handling highly sensitive materials used in advanced clinical programs. ### Why does minus 196C matter in this deal? (resonantclinical.com) Cell and gene therapy programs often depend on tightly controlled storage and transport conditions because the underlying materials can degrade if temperatures drift or handling is inconsistent. Creapharm’s vapor-phase nitrogen capability gives Resonant deeper infrastructure for those requirements in Europe. Resonant said in the acquisition release that Creapharm “strengthens our ability to support customers developing complex and sensitive therapies, including cell and gene therapies.” That framing places the deal inside the logistics layer of drug development rather than the discovery layer. (persportaal.anp.nl) ### Where does this fit inside Resonant’s existing business? Resonant says it already operates kitting, biorepository and equipment and ancillary service centers in strategic locations worldwide. (prnewswire.com) Its public materials describe the company as a global life sciences solutions business focused on clinical trial and laboratory support. The acquisition extends that network in Europe with a site and team already built around cryogenic storage and advanced-therapy support. Rather than entering a new market from scratch, Resonant is adding a specialized operating unit to an existing clinical supply chain platform. (persportaal.anp.nl) ### Who sold the business, and what was disclosed? Myonex sold Creapharm Bioservices to Resonant, according to the September 3 statement. The announcement identified Myonex as a global clinical trial supply and packaging company with operations in the United States, France and Germany. (br.advfn.com) No purchase price was disclosed in the materials surfaced from the announcement and related coverage. The companies also did not outline a closing timetable beyond stating that the acquisition had been completed and announced on September 3. (resonantclinical.com) ### What happens next for customers and trial sponsors? The clearest next step is operational integration. Resonant said Creapharm is now part of its Biorepository business, which means sponsors looking for European storage and handling support for advanced therapies will find the capability under Resonant’s existing platform. (prnewswire.com) Resonant’s website lists its services across clinical trial supply, storage and laboratory support, and the September 3 acquisition notice is the main public document describing how Creapharm fits into that network. (smb.harlandaily.com) For customers, the immediate reference points are Resonant’s Biorepository offering and the former Creapharm capabilities now folded into it. (resonantclinical.com) (prnewswire.com)